USA flag logo/image

An Official Website of the United States Government

Novel Antimicrobial Treatment in Burn Graft Biomaterials

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
60955
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
GM064847
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ACRYMED, INC.
ACRYMED, INC. 9560 SW Nimbus Ave. BEAVERTON, OR 97008
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2004
Title: Novel Antimicrobial Treatment in Burn Graft Biomaterials
Agency: HHS
Contract: 2R44GM064847-02A1
Award Amount: $696,099.00
 

Abstract:

DESCRIPTION (provided by applicant): Burn injuries represent the most terrifying and horrific trauma imaginable. This image is conditioned, in part, from the appearance of surviving bum victims that have been horribly scarred and disfigured following the healing of their injuries. Fortunately significant advances have been made that prevent these outcomes. Conventional rescue, first aid and emergency trauma have significantly improved survival of badly burned individuals. Moreover, surgical intervention and tissue repair products have greatly improved the quality of healed tissues. A notable improvement is the use of implantable collagen matrices that serve as tissue scaffolding to support the formation of neodermis. This improvement significantly decreases contraction and provides an optimal bed for split thickness grafts which overall significantly shorten healing times and improve cosmetic appearance. However collagen matrices are uniquely susceptible to colonization with bacteria because they are largely devoid of humoral and cellular defense mechanisms. Microbial colonization invariably necessitates removal of the collagen matrix, antimicrobial therapy, and repeat surgical applications. We have shown in Phase I studies that it is practical to impregnate collagen matrix with antimicrobial silver to render it inherently resistant to colonization. This phase II application proposes to extend those findings to optimize the silver impregnation protocol so as to improve collagen matrix implant materials for use in burn and deep tissue repairs and test their efficacy in an in vivo wound model. The ultimate goal of this project is to produce commercially viable silver impregnated collagen matrix that resists microbial contamination.

Principal Investigator:

Bruce L. Gibbins

Business Contact:

Jack Mcmaken
5036249830
JMCMAKEN@ACRYMED.COM
Small Business Information at Submission:

ACRYMED, INC.
ACRYMED, INC. 12232 SW GARDEN PL PORTLAND, OR 97223

EIN/Tax ID: 931134143
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No